Cadrenal Therapeutics Inc. (CVKD)

Tecarfarin Receives Orphan Drug Designation For Second Indication


Robert LeBoyerMedia Inquiries
Senior Life Sciences Analyst
April 12, 2024
Report ID: 26651
Get Report
Refer to the full report for the price target, fundamental analysis, and rating.

Equity Research provided by Noble Capital Markets is available at no cost to Registered users of Channelchek.

Already Registered? Click the ‘Get Report’ button to login and view the research report.

Not a Member? Click ‘Join’ or ‘Get Report’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.


Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc.
Healthcare
Biotechnology
Ticker
CVKD
Current Price
$0.419 1.53%
Market Cap
$6.7M
Price Target
Refer to Report
Volume
62.4K
52wk Range
$0.36 - $3.14
Related Research Reports
5/10/2024

1Q24 Reported With Preparations Continuing For Tecarfarin Phase 3
1Q24 Reported With Preparations Continuing For Tecarfarin Phase 3 (CVKD)
4/12/2024

Tecarfarin Receives Orphan Drug Designation For Second Indication
Tecarfarin Receives Orphan Drug Designation For Second Indication (CVKD)
3/13/2024

FY2023 Reported With Continued Progress Toward The Phase 3 Tecarfarin Trial
FY2023 Reported With Continued Progress Toward The Phase 3 Tecarfarin Trial (CVKD)
2/1/2024

Peer-Reviewed Journal Reviews Uses of DOAC Drugs, Pointing To The Need For Tecarfarin
Peer-Reviewed Journal Reviews Uses of DOAC Drugs, Pointing To The Need For Tecarfarin (CVKD)

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy